25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

aTyr Pharma, Inc.
Buy, Hold or Sell?

Let's analyze aTyr Pharma, Inc. together

I guess you are interested in aTyr Pharma, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of aTyr Pharma, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about aTyr Pharma, Inc.

I send you an email if I find something interesting about aTyr Pharma, Inc..

1. Quick Overview

1.1. Quick analysis of aTyr Pharma, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of aTyr Pharma, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.86
Expected worth in 1 year
$0.42
How sure are you?
14.3%

+ What do you gain per year?

Total Gains per Share
$-0.44
Return On Investment
-10.1%

For what price can you sell your share?

Current Price per Share
$4.32
Expected price per share
$3.33 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of aTyr Pharma, Inc. (5 min.)




Live pricePrice per Share (EOD)
$4.32

2.2. Growth of aTyr Pharma, Inc. (5 min.)




Is aTyr Pharma, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$65.1m$104.6m-$24.3m-30.3%

How much money is aTyr Pharma, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$15.9m-$11.8m-$4m-25.6%
Net Profit Margin-1,648.0%-1,070.8%--

How much money comes from the company's main activities?

2.3. Financial Health of aTyr Pharma, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#409 / 922

Most Revenue
#675 / 922

Most Profit
#609 / 922

Most Efficient
#742 / 922
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of aTyr Pharma, Inc.?

Welcome investor! aTyr Pharma, Inc.'s management wants to use your money to grow the business. In return you get a share of aTyr Pharma, Inc..

First you should know what it really means to hold a share of aTyr Pharma, Inc.. And how you can make/lose money.

Speculation

The Price per Share of aTyr Pharma, Inc. is $4.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of aTyr Pharma, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in aTyr Pharma, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.86. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of aTyr Pharma, Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-5.3%-0.21-4.9%-0.16-3.6%-0.19-4.3%-0.19-4.3%
Usd Book Value Change Per Share-0.21-5.0%-0.11-2.5%0.4310.0%0.122.8%0.122.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-5.0%-0.11-2.5%0.4310.0%0.122.8%0.122.8%
Usd Price Per Share1.76-1.67-1.95-1.79-1.79-
Price to Earnings Ratio-1.93--1.99--3.10--2.46--2.46-
Price-to-Total Gains Ratio-8.19--21.82--19.57--20.85--20.85-
Price to Book Ratio2.05-1.61-1.40-1.52-1.52-
Price-to-Total Gains Ratio-8.19--21.82--19.57--20.85--20.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.32
Number of shares231
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.12
Usd Total Gains Per Share-0.110.12
Gains per Quarter (231 shares)-25.2028.36
Gains per Year (231 shares)-100.78113.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-101-1110113103
20-202-2120227216
30-302-3130340329
40-403-4140454442
50-504-5150567555
60-605-6160681668
70-705-7170794781
80-806-8180907894
90-907-919010211007
100-1008-1020011341120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.07.00.00.0%0.07.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.06.00.014.3%1.06.00.014.3%1.06.00.014.3%1.06.00.014.3%
Dividend per Share0.00.04.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share0.04.00.00.0%1.06.00.014.3%1.06.00.014.3%1.06.00.014.3%1.06.00.014.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of aTyr Pharma, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.215-0.109-49%0.432-150%0.123-275%0.123-275%
Book Value Per Share--0.8591.060-19%1.381-38%1.197-28%1.197-28%
Current Ratio--5.4066.343-15%8.777-38%7.386-27%7.386-27%
Debt To Asset Ratio--0.2890.259+12%0.205+41%0.236+23%0.236+23%
Debt To Equity Ratio--0.4050.349+16%0.257+58%0.310+31%0.310+31%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--172920932.160180475309.040-4%154693269.333+12%169425863.451+2%169425863.451+2%
Eps---0.228-0.210-8%-0.157-31%-0.187-18%-0.187-18%
Ev To Ebitda Ratio---2.435-2.742+13%infnan%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.174-0.221+27%-0.116-33%-0.176+1%-0.176+1%
Free Cash Flow To Equity Per Share---0.175-0.132-25%0.149-218%-0.012-93%-0.012-93%
Gross Profit Margin--1.0001.025-2%1.029-3%1.027-3%1.027-3%
Market Cap327439584.000+59%133410932.160126582059.040+5%147549936.000-10%135568292.023-2%135568292.023-2%
Net Profit Margin----16.4800%-10.7080%-14.0060%-14.0060%
Operating Margin----17.6980%-11.9120%-15.2180%-15.2180%
Operating Ratio---17.948-100%12.246-100%15.504-100%15.504-100%
Pb Ratio5.027+59%2.0481.609+27%1.405+46%1.521+35%1.521+35%
Pe Ratio-4.743-145%-1.932-1.985+3%-3.096+60%-2.461+27%-2.461+27%
Price Per Share4.320+59%1.7601.670+5%1.947-10%1.789-2%1.789-2%
Price To Free Cash Flow Ratio-6.215-145%-2.532-2.010-21%-9.158+262%-5.073+100%-5.073+100%
Price To Total Gains Ratio-20.101-145%-8.189-21.817+166%-19.570+139%-20.854+155%-20.854+155%
Quick Ratio--8.66610.632-18%9.969-13%10.348-16%10.348-16%
Return On Assets---0.188-0.150-20%-0.090-52%-0.124-34%-0.124-34%
Return On Equity---0.264-0.203-23%-0.113-57%-0.164-38%-0.164-38%
Total Gains Per Share---0.215-0.109-49%0.432-150%0.123-275%0.123-275%
Usd Book Value--65139000.00080328750.000-19%104651000.000-38%90752571.429-28%90752571.429-28%
Usd Book Value Change Per Share---0.215-0.109-49%0.432-150%0.123-275%0.123-275%
Usd Book Value Per Share--0.8591.060-19%1.381-38%1.197-28%1.197-28%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--172920932.160180475309.040-4%154693269.333+12%169425863.451+2%169425863.451+2%
Usd Eps---0.228-0.210-8%-0.157-31%-0.187-18%-0.187-18%
Usd Free Cash Flow---13173000.000-16776500.000+27%-8785666.667-33%-13351857.143+1%-13351857.143+1%
Usd Free Cash Flow Per Share---0.174-0.221+27%-0.116-33%-0.176+1%-0.176+1%
Usd Free Cash Flow To Equity Per Share---0.175-0.132-25%0.149-218%-0.012-93%-0.012-93%
Usd Market Cap327439584.000+59%133410932.160126582059.040+5%147549936.000-10%135568292.023-2%135568292.023-2%
Usd Price Per Share4.320+59%1.7601.670+5%1.947-10%1.789-2%1.789-2%
Usd Profit---17259000.000-15954000.000-8%-11876333.333-31%-14206428.571-18%-14206428.571-18%
Usd Revenue---58750.000-100%117666.667-100%84000.000-100%84000.000-100%
Usd Total Gains Per Share---0.215-0.109-49%0.432-150%0.123-275%0.123-275%
 EOD+5 -3MRQTTM+10 -25YOY+5 -295Y+8 -2610Y+8 -26

3.3 Fundamental Score

Let's check the fundamental score of aTyr Pharma, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.743
Price to Book Ratio (EOD)Between0-15.027
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.666
Current Ratio (MRQ)Greater than15.406
Debt to Asset Ratio (MRQ)Less than10.289
Debt to Equity Ratio (MRQ)Less than10.405
Return on Equity (MRQ)Greater than0.15-0.264
Return on Assets (MRQ)Greater than0.05-0.188
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of aTyr Pharma, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.393
Ma 20Greater thanMa 503.785
Ma 50Greater thanMa 1003.602
Ma 100Greater thanMa 2003.241
OpenGreater thanClose4.560
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-02-17 00:08:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit aTyr Pharma, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of aTyr Pharma, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,648.0%+1,648.0%
TTM-1,648.0%YOY-1,070.8%-577.2%
TTM-1,648.0%5Y-1,400.6%-247.4%
5Y-1,400.6%10Y-1,400.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--99.4%+99.4%
TTM-1,648.0%-211.5%-1,436.5%
YOY-1,070.8%-210.1%-860.7%
5Y-1,400.6%-346.2%-1,054.4%
10Y-1,400.6%-489.2%-911.4%
4.3.1.2. Return on Assets

Shows how efficient aTyr Pharma, Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • -18.8% Return on Assets means that aTyr Pharma, Inc. generated $-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of aTyr Pharma, Inc.:

  • The MRQ is -18.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.8%TTM-15.0%-3.8%
TTM-15.0%YOY-9.0%-6.0%
TTM-15.0%5Y-12.4%-2.6%
5Y-12.4%10Y-12.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.8%-12.0%-6.8%
TTM-15.0%-12.1%-2.9%
YOY-9.0%-11.4%+2.4%
5Y-12.4%-12.8%+0.4%
10Y-12.4%-14.5%+2.1%
4.3.1.3. Return on Equity

Shows how efficient aTyr Pharma, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • -26.4% Return on Equity means aTyr Pharma, Inc. generated $-0.26 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of aTyr Pharma, Inc.:

  • The MRQ is -26.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.4%TTM-20.3%-6.2%
TTM-20.3%YOY-11.3%-8.9%
TTM-20.3%5Y-16.4%-3.8%
5Y-16.4%10Y-16.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.4%-15.4%-11.0%
TTM-20.3%-16.1%-4.2%
YOY-11.3%-14.7%+3.4%
5Y-16.4%-18.5%+2.1%
10Y-16.4%-19.5%+3.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of aTyr Pharma, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient aTyr Pharma, Inc. is operating .

  • Measures how much profit aTyr Pharma, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of aTyr Pharma, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,769.8%+1,769.8%
TTM-1,769.8%YOY-1,191.2%-578.6%
TTM-1,769.8%5Y-1,521.8%-248.0%
5Y-1,521.8%10Y-1,521.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--202.6%+202.6%
TTM-1,769.8%-313.2%-1,456.6%
YOY-1,191.2%-214.2%-977.0%
5Y-1,521.8%-371.8%-1,150.0%
10Y-1,521.8%-492.1%-1,029.7%
4.3.2.2. Operating Ratio

Measures how efficient aTyr Pharma, Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of aTyr Pharma, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM17.948-17.948
TTM17.948YOY12.246+5.702
TTM17.9485Y15.504+2.444
5Y15.50410Y15.5040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.129-2.129
TTM17.9483.198+14.750
YOY12.2463.358+8.888
5Y15.5044.842+10.662
10Y15.5046.500+9.004
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of aTyr Pharma, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if aTyr Pharma, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.41 means the company has $5.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of aTyr Pharma, Inc.:

  • The MRQ is 5.406. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.343. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.406TTM6.343-0.938
TTM6.343YOY8.777-2.433
TTM6.3435Y7.386-1.043
5Y7.38610Y7.3860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4063.608+1.798
TTM6.3433.871+2.472
YOY8.7774.591+4.186
5Y7.3865.971+1.415
10Y7.3866.216+1.170
4.4.3.2. Quick Ratio

Measures if aTyr Pharma, Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 8.67 means the company can pay off $8.67 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of aTyr Pharma, Inc.:

  • The MRQ is 8.666. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.632. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.666TTM10.632-1.966
TTM10.632YOY9.969+0.664
TTM10.6325Y10.348+0.284
5Y10.34810Y10.3480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6663.075+5.591
TTM10.6323.351+7.281
YOY9.9694.393+5.576
5Y10.3485.972+4.376
10Y10.3486.463+3.885
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of aTyr Pharma, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of aTyr Pharma, Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare aTyr Pharma, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that aTyr Pharma, Inc. assets are financed with 28.9% credit (debt) and the remaining percentage (100% - 28.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of aTyr Pharma, Inc.:

  • The MRQ is 0.289. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.259. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.289TTM0.259+0.030
TTM0.259YOY0.205+0.054
TTM0.2595Y0.236+0.023
5Y0.23610Y0.2360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2890.342-0.053
TTM0.2590.345-0.086
YOY0.2050.315-0.110
5Y0.2360.363-0.127
10Y0.2360.384-0.148
4.5.4.2. Debt to Equity Ratio

Measures if aTyr Pharma, Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.5% means that company has $0.41 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of aTyr Pharma, Inc.:

  • The MRQ is 0.405. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.349. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.405TTM0.349+0.056
TTM0.349YOY0.257+0.092
TTM0.3495Y0.310+0.040
5Y0.31010Y0.3100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4050.387+0.018
TTM0.3490.428-0.079
YOY0.2570.391-0.134
5Y0.3100.450-0.140
10Y0.3100.495-0.185
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings aTyr Pharma, Inc. generates.

  • Above 15 is considered overpriced but always compare aTyr Pharma, Inc. to the Biotechnology industry mean.
  • A PE ratio of -1.93 means the investor is paying $-1.93 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of aTyr Pharma, Inc.:

  • The EOD is -4.743. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.932. Based on the earnings, the company is expensive. -2
  • The TTM is -1.985. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.743MRQ-1.932-2.811
MRQ-1.932TTM-1.985+0.053
TTM-1.985YOY-3.096+1.111
TTM-1.9855Y-2.461+0.476
5Y-2.46110Y-2.4610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.743-2.261-2.482
MRQ-1.932-2.752+0.820
TTM-1.985-3.224+1.239
YOY-3.096-3.405+0.309
5Y-2.461-6.128+3.667
10Y-2.461-6.735+4.274
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of aTyr Pharma, Inc.:

  • The EOD is -6.215. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.532. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.010. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.215MRQ-2.532-3.683
MRQ-2.532TTM-2.010-0.522
TTM-2.010YOY-9.158+7.149
TTM-2.0105Y-5.073+3.064
5Y-5.07310Y-5.0730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.215-3.073-3.142
MRQ-2.532-3.602+1.070
TTM-2.010-3.827+1.817
YOY-9.158-4.448-4.710
5Y-5.073-8.209+3.136
10Y-5.073-9.216+4.143
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of aTyr Pharma, Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.05 means the investor is paying $2.05 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of aTyr Pharma, Inc.:

  • The EOD is 5.027. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.048. Based on the equity, the company is underpriced. +1
  • The TTM is 1.609. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.027MRQ2.048+2.979
MRQ2.048TTM1.609+0.439
TTM1.609YOY1.405+0.204
TTM1.6095Y1.521+0.087
5Y1.52110Y1.5210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.0271.942+3.085
MRQ2.0482.252-0.204
TTM1.6092.427-0.818
YOY1.4052.470-1.065
5Y1.5213.770-2.249
10Y1.5214.507-2.986
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of aTyr Pharma, Inc..

4.8.3. Insider Transactions

Insiders are holding 2.391% of the shares of aTyr Pharma, Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-02-04Jill Marie BroadfootSELL12543.78
2025-02-04Nancy DenyesSELL8993.78
2024-07-24Paul SchimmelBUY523001.93
2024-07-22Paul SchimmelBUY410521.74
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -294220-74-84-158-10-16820436



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets91,616
Total Liabilities26,477
Total Stockholder Equity65,325
 As reported
Total Liabilities 26,477
Total Stockholder Equity+ 65,325
Total Assets = 91,616

Assets

Total Assets91,616
Total Current Assets76,317
Long-term Assets15,299
Total Current Assets
Cash And Cash Equivalents 11,458
Short-term Investments 54,529
Net Receivables 1,831
Other Current Assets 8,499
Total Current Assets  (as reported)76,317
Total Current Assets  (calculated)76,317
+/-0
Long-term Assets
Property Plant Equipment 12,243
Long-term Assets Other 3,056
Long-term Assets  (as reported)15,299
Long-term Assets  (calculated)15,299
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,118
Long-term Liabilities12,359
Total Stockholder Equity65,325
Total Current Liabilities
Short-term Debt 1,211
Accounts payable 3,949
Other Current Liabilities 8,958
Total Current Liabilities  (as reported)14,118
Total Current Liabilities  (calculated)14,118
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt12,359
Long-term Liabilities  (as reported)12,359
Long-term Liabilities  (calculated)12,359
+/-0
Total Stockholder Equity
Common Stock76
Retained Earnings -517,079
Accumulated Other Comprehensive Income 36
Other Stockholders Equity 582,292
Total Stockholder Equity (as reported)65,325
Total Stockholder Equity (calculated)65,325
+/-0
Other
Capital Stock76
Cash and Short Term Investments 65,987
Common Stock Shares Outstanding 75,802
Liabilities and Stockholders Equity 91,616
Net Debt 2,112
Net Invested Capital 65,325
Net Working Capital 62,199
Property Plant and Equipment Gross 12,243
Short Long Term Debt Total 13,570



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
> Total Assets 
0
0
136,838
132,747
125,069
122,067
113,251
105,939
91,616
91,616105,939113,251122,067125,069132,747136,83800
   > Total Current Assets 
0
0
119,447
114,431
107,298
102,992
96,916
90,297
76,317
76,31790,29796,916102,992107,298114,431119,44700
       Cash And Cash Equivalents 
0
0
20,690
12,313
9,787
22,544
6,808
6,805
11,458
11,4586,8056,80822,5449,78712,31320,69000
       Short-term Investments 
0
0
93,695
96,268
92,344
75,622
77,688
71,677
54,529
54,52971,67777,68875,62292,34496,26893,69500
       Net Receivables 
0
0
0
0
2,087
2,436
2,476
1,628
1,831
1,8311,6282,4762,4362,0870000
   > Long-term Assets 
0
0
17,391
18,316
17,771
19,075
16,335
15,642
15,299
15,29915,64216,33519,07517,77118,31617,39100
       Property Plant Equipment 
0
0
14,057
14,825
14,247
14,046
12,991
12,616
12,243
12,24312,61612,99114,04614,24714,82514,05700
       Other Assets 
0
0
0
0
0
0
0
0
0
000000000
> Total Liabilities 
0
0
27,140
26,695
26,866
31,597
28,969
24,515
26,477
26,47724,51528,96931,59726,86626,69527,14000
   > Total Current Liabilities 
0
0
13,654
12,368
12,881
16,416
15,979
11,837
14,118
14,11811,83715,97916,41612,88112,36813,65400
       Short-term Debt 
0
0
0
0
1,233
1,328
1,136
1,173
1,211
1,2111,1731,1361,3281,2330000
       Accounts payable 
0
0
3,965
516
2,043
3,529
4,893
1,255
3,949
3,9491,2554,8933,5292,0435163,96500
       Other Current Liabilities 
0
0
0
0
9,605
11,559
9,950
9,409
8,958
8,9589,4099,95011,5599,6050000
   > Long-term Liabilities 
0
0
13,486
14,327
13,985
15,181
12,990
12,678
12,359
12,35912,67812,99015,18113,98514,32713,48600
> Total Stockholder Equity
0
0
109,879
106,237
98,390
90,658
84,466
81,608
65,325
65,32581,60884,46690,65898,390106,237109,87900
   Common Stock
0
0
0
0
59
63
68
76
76
76766863590000
   Retained Earnings Total Equity000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-294
-74
-158
-168
36
36-168-158-74-2940000
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
0
0
0
0
551,888
558,692
568,070
581,520
582,292
582,292581,520568,070558,692551,8880000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue353
Cost of Revenue-2,741
Gross Profit-2,388-2,388
 
Operating Income (+$)
Gross Profit-2,388
Operating Expense-55,272
Operating Income-54,919-57,660
 
Operating Expense (+$)
Research Development42,293
Selling General Administrative12,979
Selling And Marketing Expenses2,741
Operating Expense55,27258,013
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-54,919
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-50,397-59,441
EBIT - interestExpense = -54,919
-50,397
-50,389
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-54,919-50,397
Earnings Before Interest and Taxes (EBITDA)-52,178
 
After tax Income (+$)
Income Before Tax-50,397
Tax Provision-0
Net Income From Continuing Ops-50,397-50,397
Net Income-50,389
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses55,272
Total Other Income/Expenses Net4,5220
 

Technical Analysis of aTyr Pharma, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of aTyr Pharma, Inc.. The general trend of aTyr Pharma, Inc. is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine aTyr Pharma, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of aTyr Pharma, Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 4.225 > 3.99 > 3.33.

Tweet this
aTyr Pharma, Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of aTyr Pharma, Inc.. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

aTyr Pharma, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of aTyr Pharma, Inc.. The current macd is 0.15044693.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the aTyr Pharma, Inc. price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for aTyr Pharma, Inc.. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the aTyr Pharma, Inc. price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
aTyr Pharma, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartaTyr Pharma, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of aTyr Pharma, Inc.. The current adx is 15.30.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy aTyr Pharma, Inc. shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
aTyr Pharma, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of aTyr Pharma, Inc.. The current sar is 3.445176.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
aTyr Pharma, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of aTyr Pharma, Inc.. The current rsi is 63.39. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
aTyr Pharma, Inc. Daily Relative Strength Index (RSI) ChartaTyr Pharma, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of aTyr Pharma, Inc.. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the aTyr Pharma, Inc. price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
aTyr Pharma, Inc. Daily Stochastic Oscillator ChartaTyr Pharma, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of aTyr Pharma, Inc.. The current cci is 216.14.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
aTyr Pharma, Inc. Daily Commodity Channel Index (CCI) ChartaTyr Pharma, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of aTyr Pharma, Inc.. The current cmo is 33.10.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
aTyr Pharma, Inc. Daily Chande Momentum Oscillator (CMO) ChartaTyr Pharma, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of aTyr Pharma, Inc.. The current willr is -25.56390977.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that aTyr Pharma, Inc. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
aTyr Pharma, Inc. Daily Williams %R ChartaTyr Pharma, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of aTyr Pharma, Inc..

aTyr Pharma, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of aTyr Pharma, Inc.. The current atr is 0.28763041.

aTyr Pharma, Inc. Daily Average True Range (ATR) ChartaTyr Pharma, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of aTyr Pharma, Inc.. The current obv is 49,736,366.

aTyr Pharma, Inc. Daily On-Balance Volume (OBV) ChartaTyr Pharma, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of aTyr Pharma, Inc.. The current mfi is 67.42.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
aTyr Pharma, Inc. Daily Money Flow Index (MFI) ChartaTyr Pharma, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for aTyr Pharma, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

aTyr Pharma, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of aTyr Pharma, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.393
Ma 20Greater thanMa 503.785
Ma 50Greater thanMa 1003.602
Ma 100Greater thanMa 2003.241
OpenGreater thanClose4.560
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of aTyr Pharma, Inc. with someone you think should read this too:
  • Are you bullish or bearish on aTyr Pharma, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about aTyr Pharma, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about aTyr Pharma, Inc.

I send you an email if I find something interesting about aTyr Pharma, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about aTyr Pharma, Inc..

Receive notifications about aTyr Pharma, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.